Spatiotemporal delivery of nanoformulated liraglutide for cardiac regeneration after myocardial infarction

Quan Qi,1,* Lei Lu,2,3,* Haiqing Li,1,* Zhize Yuan,1 Gaoxian Chen,2,3 Miao Lin,2,3 Zhengwen Ruan,4 Xiaofeng Ye,1 Zeyu Xiao,2,3,5 Qiang Zhao1 1Department of Cardiac Surgery, Rui Jin Hospital, 2Department of Pharmacology, Institute of Medical Sciences, 3Translational Medicine Collaborative Innovation...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Qi Q, Lu L, Li H, Yuan Z, Chen G, Lin M, Ruan Z, Ye X, Xiao Z, Zhao Q
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2017
Materias:	Spatiotemporal Delivery Nanoformulated Liraglutide Cardiac Regeneration Medicine (General) R5-920
Acceso en línea:	https://doaj.org/article/f7cadb78cb7d40b198b0615f85eb940e
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:f7cadb78cb7d40b198b0615f85eb940e
record_format	dspace
spelling	oai:doaj.org-article:f7cadb78cb7d40b198b0615f85eb940e2021-12-02T00:40:25ZSpatiotemporal delivery of nanoformulated liraglutide for cardiac regeneration after myocardial infarction1178-2013https://doaj.org/article/f7cadb78cb7d40b198b0615f85eb940e2017-07-01T00:00:00Zhttps://www.dovepress.com/spatiotemporal-delivery-of-nanoformulated-liraglutide-for-cardiac-rege-peer-reviewed-article-IJNhttps://doaj.org/toc/1178-2013Quan Qi,1,* Lei Lu,2,3,* Haiqing Li,1,* Zhize Yuan,1 Gaoxian Chen,2,3 Miao Lin,2,3 Zhengwen Ruan,4 Xiaofeng Ye,1 Zeyu Xiao,2,3,5 Qiang Zhao1 1Department of Cardiac Surgery, Rui Jin Hospital, 2Department of Pharmacology, Institute of Medical Sciences, 3Translational Medicine Collaborative Innovation Center, Shanghai Jiao Tong University School of Medicine, Shanghai, 4Department of Cardiology, Yuyao People’s Hospital, Yuyao, Zhejiang, 5Collaborative Innovation Center of Systems Biomedicine, Shanghai Jiao Tong University School of Medicine, Shanghai, People’s Republic of China *These authors contributed equally to this work Abstract: The local, intramyocardial injection of proteins into the infarcted heart is an attractive option to initiate cardiac regeneration after myocardial infarction (MI). Liraglutide, which was developed as a treatment for type 2 diabetes, has been implicated as one of the most promising protein candidates in cardiac regeneration. A significant challenge to the therapeutic use of this protein is its short half-life in vivo. In this study, we evaluated the therapeutic effects and long-term retention of liraglutide loaded in poly(lactic-co-glycolic acid)–poly(ethylene glycol) (PLGA–PEG) nanoparticles (NP-liraglutide) on experimental MI. PLGA–PEG nanoparticles (NPs) have been shown to efficiently load liraglutide and release bioactive liraglutide in a sustained manner. For in vitro test, the released liraglutide retained bioactivity, as measured by its ability to activate liraglutide signaling pathways. Next, we compared the effects of an intramyocardial injection of saline, empty NPs, free liraglutide and NP-liraglutide in a rat model of MI. NPs were detected in the myocardium for up to 4 weeks. More importantly, an intramyocardial injection of NP-liraglutide was sufficient to improve cardiac function (P<0.05), attenuate the infarct size (P<0.05), preserve wall thickness (P<0.05), promote angiogenesis (P<0.05) and prevent cardiomyocyte apoptosis (P<0.05) at 4 weeks after injection without affecting glucose levels. The local, controlled, intramyocardial delivery of NP-liraglutide represents an effective and promising strategy for the treatment of MI. Keywords: spatiotemporal delivery, nanoformulated liraglutide, cardiac regeneration Qi QLu LLi HYuan ZChen GLin MRuan ZYe XXiao ZZhao QDove Medical PressarticleSpatiotemporal DeliveryNanoformulated LiraglutideCardiac RegenerationMedicine (General)R5-920ENInternational Journal of Nanomedicine, Vol Volume 12, Pp 4835-4848 (2017)
institution	DOAJ
collection	DOAJ
language	EN
topic	Spatiotemporal Delivery Nanoformulated Liraglutide Cardiac Regeneration Medicine (General) R5-920
spellingShingle	Spatiotemporal Delivery Nanoformulated Liraglutide Cardiac Regeneration Medicine (General) R5-920 Qi Q Lu L Li H Yuan Z Chen G Lin M Ruan Z Ye X Xiao Z Zhao Q Spatiotemporal delivery of nanoformulated liraglutide for cardiac regeneration after myocardial infarction
description	Quan Qi,1,* Lei Lu,2,3,* Haiqing Li,1,* Zhize Yuan,1 Gaoxian Chen,2,3 Miao Lin,2,3 Zhengwen Ruan,4 Xiaofeng Ye,1 Zeyu Xiao,2,3,5 Qiang Zhao1 1Department of Cardiac Surgery, Rui Jin Hospital, 2Department of Pharmacology, Institute of Medical Sciences, 3Translational Medicine Collaborative Innovation Center, Shanghai Jiao Tong University School of Medicine, Shanghai, 4Department of Cardiology, Yuyao People’s Hospital, Yuyao, Zhejiang, 5Collaborative Innovation Center of Systems Biomedicine, Shanghai Jiao Tong University School of Medicine, Shanghai, People’s Republic of China *These authors contributed equally to this work Abstract: The local, intramyocardial injection of proteins into the infarcted heart is an attractive option to initiate cardiac regeneration after myocardial infarction (MI). Liraglutide, which was developed as a treatment for type 2 diabetes, has been implicated as one of the most promising protein candidates in cardiac regeneration. A significant challenge to the therapeutic use of this protein is its short half-life in vivo. In this study, we evaluated the therapeutic effects and long-term retention of liraglutide loaded in poly(lactic-co-glycolic acid)–poly(ethylene glycol) (PLGA–PEG) nanoparticles (NP-liraglutide) on experimental MI. PLGA–PEG nanoparticles (NPs) have been shown to efficiently load liraglutide and release bioactive liraglutide in a sustained manner. For in vitro test, the released liraglutide retained bioactivity, as measured by its ability to activate liraglutide signaling pathways. Next, we compared the effects of an intramyocardial injection of saline, empty NPs, free liraglutide and NP-liraglutide in a rat model of MI. NPs were detected in the myocardium for up to 4 weeks. More importantly, an intramyocardial injection of NP-liraglutide was sufficient to improve cardiac function (P<0.05), attenuate the infarct size (P<0.05), preserve wall thickness (P<0.05), promote angiogenesis (P<0.05) and prevent cardiomyocyte apoptosis (P<0.05) at 4 weeks after injection without affecting glucose levels. The local, controlled, intramyocardial delivery of NP-liraglutide represents an effective and promising strategy for the treatment of MI. Keywords: spatiotemporal delivery, nanoformulated liraglutide, cardiac regeneration
format	article
author	Qi Q Lu L Li H Yuan Z Chen G Lin M Ruan Z Ye X Xiao Z Zhao Q
author_facet	Qi Q Lu L Li H Yuan Z Chen G Lin M Ruan Z Ye X Xiao Z Zhao Q
author_sort	Qi Q
title	Spatiotemporal delivery of nanoformulated liraglutide for cardiac regeneration after myocardial infarction
title_short	Spatiotemporal delivery of nanoformulated liraglutide for cardiac regeneration after myocardial infarction
title_full	Spatiotemporal delivery of nanoformulated liraglutide for cardiac regeneration after myocardial infarction
title_fullStr	Spatiotemporal delivery of nanoformulated liraglutide for cardiac regeneration after myocardial infarction
title_full_unstemmed	Spatiotemporal delivery of nanoformulated liraglutide for cardiac regeneration after myocardial infarction
title_sort	spatiotemporal delivery of nanoformulated liraglutide for cardiac regeneration after myocardial infarction
publisher	Dove Medical Press
publishDate	2017
url	https://doaj.org/article/f7cadb78cb7d40b198b0615f85eb940e
work_keys_str_mv	AT qiq spatiotemporaldeliveryofnanoformulatedliraglutideforcardiacregenerationaftermyocardialinfarction AT lul spatiotemporaldeliveryofnanoformulatedliraglutideforcardiacregenerationaftermyocardialinfarction AT lih spatiotemporaldeliveryofnanoformulatedliraglutideforcardiacregenerationaftermyocardialinfarction AT yuanz spatiotemporaldeliveryofnanoformulatedliraglutideforcardiacregenerationaftermyocardialinfarction AT cheng spatiotemporaldeliveryofnanoformulatedliraglutideforcardiacregenerationaftermyocardialinfarction AT linm spatiotemporaldeliveryofnanoformulatedliraglutideforcardiacregenerationaftermyocardialinfarction AT ruanz spatiotemporaldeliveryofnanoformulatedliraglutideforcardiacregenerationaftermyocardialinfarction AT yex spatiotemporaldeliveryofnanoformulatedliraglutideforcardiacregenerationaftermyocardialinfarction AT xiaoz spatiotemporaldeliveryofnanoformulatedliraglutideforcardiacregenerationaftermyocardialinfarction AT zhaoq spatiotemporaldeliveryofnanoformulatedliraglutideforcardiacregenerationaftermyocardialinfarction
_version_	1718403592867545088

Spatiotemporal delivery of nanoformulated liraglutide for cardiac regeneration after myocardial infarction

Ejemplares similares